A detailed history of Raymond James & Associates transactions in Takeda Pharmaceutical CO LTD stock. As of the latest transaction made, Raymond James & Associates holds 193,566 shares of TAK stock, worth $2.62 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
193,566
Previous 255,762 24.32%
Holding current value
$2.62 Million
Previous $3.31 Million 16.89%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$13.0 - $15.08 $808,548 - $937,915
-62,196 Reduced 24.32%
193,566 $2.75 Million
Q2 2024

Jul 19, 2024

BUY
$12.6 - $13.67 $162,061 - $175,823
12,862 Added 5.3%
255,762 $3.31 Million
Q1 2024

Apr 22, 2024

BUY
$13.89 - $15.04 $285,175 - $308,786
20,531 Added 9.23%
242,900 $3.37 Million
Q4 2023

Jan 16, 2024

BUY
$13.36 - $15.43 $763,310 - $881,577
57,134 Added 34.58%
222,369 $3.17 Million
Q3 2023

Oct 24, 2023

SELL
$15.03 - $16.32 $101,452 - $110,160
-6,750 Reduced 3.92%
165,235 $2.56 Million
Q2 2023

Jul 25, 2023

BUY
$15.57 - $17.11 $458,069 - $503,376
29,420 Added 20.64%
171,985 $2.7 Million
Q1 2023

Apr 14, 2023

BUY
$15.28 - $16.48 $225,548 - $243,261
14,761 Added 11.55%
142,565 $2.35 Million
Q4 2022

Feb 08, 2023

BUY
$12.42 - $15.62 $309,866 - $389,703
24,949 Added 24.26%
127,804 $2 Million
Q3 2022

Oct 25, 2022

SELL
$12.8 - $28.65 $127,142 - $284,580
-9,933 Reduced 8.81%
102,855 $1.33 Million
Q2 2022

Aug 12, 2022

SELL
$13.12 - $15.03 $255,026 - $292,153
-19,438 Reduced 14.7%
112,788 $1.58 Million
Q1 2022

May 11, 2022

BUY
$13.54 - $15.35 $393,837 - $446,485
29,087 Added 28.2%
132,226 $1.89 Million
Q4 2021

Feb 08, 2022

SELL
$13.17 - $16.4 $1.61 Million - $2.01 Million
-122,402 Reduced 54.27%
103,139 $1.41 Million
Q3 2021

Nov 02, 2021

SELL
$16.3 - $17.26 $287,385 - $304,311
-17,631 Reduced 7.25%
225,541 $3.69 Million
Q2 2021

Aug 11, 2021

BUY
$16.55 - $18.64 $273,737 - $308,305
16,540 Added 7.3%
243,172 $4.09 Million
Q1 2021

May 14, 2021

SELL
$16.71 - $19.9 $13.1 Million - $15.6 Million
-783,817 Reduced 77.57%
226,632 $4.14 Million
Q4 2020

Feb 12, 2021

SELL
$15.39 - $18.97 $1.24 Million - $1.53 Million
-80,564 Reduced 7.38%
1,010,449 $18.4 Million
Q3 2020

Nov 04, 2020

SELL
$17.1 - $19.19 $1.26 Million - $1.42 Million
-73,894 Reduced 6.34%
1,091,013 $19.5 Million
Q2 2020

Jul 28, 2020

SELL
$14.59 - $19.5 $690,457 - $922,818
-47,324 Reduced 3.9%
1,164,907 $20.9 Million
Q1 2020

Apr 21, 2020

BUY
$13.02 - $20.31 $2.27 Million - $3.55 Million
174,691 Added 16.84%
1,212,231 $18.4 Million
Q4 2019

Feb 12, 2020

BUY
$16.88 - $20.83 $1.44 Million - $1.78 Million
85,410 Added 8.97%
1,037,540 $20.5 Million
Q3 2019

Nov 07, 2019

BUY
$16.15 - $17.99 $4.25 Million - $4.74 Million
263,461 Added 38.26%
952,130 $16.4 Million
Q2 2019

Aug 06, 2019

BUY
$16.58 - $20.49 $3.09 Million - $3.82 Million
186,425 Added 37.12%
688,669 $12.2 Million
Q1 2019

May 06, 2019

BUY
$16.7 - $21.52 $7.67 Million - $9.88 Million
459,051 Added 1062.79%
502,244 $10.2 Million
Q4 2018

Feb 11, 2019

BUY
$15.64 - $21.1 $675,538 - $911,372
43,193 New
43,193 $727,000

Others Institutions Holding TAK

About TAKEDA PHARMACEUTICAL CO LTD


  • Ticker TAK
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 3,109,050,112
  • Market Cap $42.2B
  • Description
  • Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...
More about TAK
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.